University of Arkansas For Medical Sciences
Little Rock, Arkansas, 72205, United States
NCT Number: NCT00575029
Megestrol Acetate (MA) is a progesterone-like hormone that has been utilized as a birth control agent, chemotherapeutic drug, and more recently, to induce appetite and weight gain in patients malnourished as a result of radiation therapy, chemotherapy, cystic fibrosis, AIDS, or dementia. The mechanism of MA-stimulated appetite and weight gain is unknown.
Although only approved to combat weight loss associated with AIDS and cancer, MA is frequently prescribed for long periods of time to prevent or reverse weight loss in nursing home residents and in elderly patients with serious illnesses in the community. Little data is available to support this practice. Among its many properties, MA acts as a partial glucocorticoid agonist, and long term and short term use of MA may results in adrenal suppression. The rapidity of the onset of MA-induced adrenal suppression and the time course of resumption of normal adrenal function after discontinuation of MA is completely unknown. As a consequence, it is unclear whether MA can be given safely for short periods of time or whether glucocorticoid administration is necessary after abruptly stopping MA treatment. The increased use of MA in the frail elderly, where even partial adrenal insufficiency may pose a substantial risk of adrenal crisis after an illness, requires a clear understanding of these issues. To address these concerns, we will evaluate adrenal function before, during, and after MA administration in healthy volunteers between the ages of 60 and 85 years.
Looking for future studies?
Notify Me65 year–80 year
All sexes
Interventional
Not applicable
Little Rock, Arkansas, 72205, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will be excluded if they have a history of (H/O):
600 mg by mouth daily
Time frame: stimulated acth stimulated cortisol levels weekly for 8 weeks or until adrenal insufficiency is encountered
Number of participants with adrenal insufficiency after treatment with megestrol acetate assessed by ACTH stimulated cortisol levels less than normal (21 ug/dl) measured weekly for 8 weeks or when adrenal insufficiency is clinically encountered
Time frame: weekly for up to 6 weeks
the number of weeks required for participants to recover from adrenal suppression as assessed by a normal ACTH stimulation test (cortisol level >21 mcg/dl)
University of Arkansas
Other
Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00156767
Adrenal Gland Diseases, Adrenal Insufficiency
Bethesda, Maryland, United States
View Trial DetailsNCT06608433
Adrenal Gland Diseases, Adrenal Insufficiency
Basel, Switzerland
View Trial DetailsNCT04642391
Adrenal Gland Diseases, Adrenal Insufficiency
Charlottesville, Virginia, United States
View Trial DetailsNCT03294876
Adrenal Gland Diseases, Adrenal Insufficiency
Edinburgh, Scotland, United Kingdom
View Trial Details